Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medical Imaging
Published in: BMC Medical Imaging 1/2016

Open Access 01-12-2016 | Research article

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis

Authors: Sheena L. Dupuy, Fariha Khalid, Brian C. Healy, Sonya Bakshi, Mohit Neema, Shahamat Tauhid, Rohit Bakshi

Published in: BMC Medical Imaging | Issue 1/2016

Login to get access

Abstract

Background

Spinal cord atrophy occurs early in multiple sclerosis (MS) and impacts disability. The therapeutic effect of interferon beta-1a (IFNβ-1a) on spinal cord atrophy in patients with relapsing-remitting (RR) MS has not been explored.

Methods

We retrospectively identified 16 consecutive patients receiving weekly intramuscular IFNβ-1a for 2 years [baseline age (mean ± SD) 47.7 ± 7.5 years, Expanded Disability Status Scale score median (range) 1.5 (0–2.5), timed 25-foot walk 4.6 ± 0.7 seconds; time on treatment 68.3 ± 59.9 months] and 11 sex- and age-matched normal controls (NC). The spinal cord was imaged at baseline, 1 and 2 years later with 3T MRI. C1-C5 spinal cord volume was measured by an active surface method, from which normalized spinal cord area (SCA) was calculated.

Results

SCA showed no change in the MS or NC group over 2 years [mean annualized difference (95 % CI) MS: −0.604 mm2 (−1.352, 0.144), p = 0.106; NC: −0.360 mm2 (−1.576, 0.855), p = 0.524]. Between group analysis indicated no differences in on-study SCA change [MS vs. NC; year 1 vs. baseline, mean annualized difference (95 % CI) 0.400 mm2 (−3.350, 2.549), p = 0.780; year 2 vs. year 1: −1.196 mm2 (−0.875, 3.266), p = 0.245; year 2 vs. baseline −0.243 mm2 (−1.120, 1.607), p = 0.712].

Conclusion

Established IFNβ-1a therapy was not associated with ongoing spinal cord atrophy or any difference in the rate of spinal cord volume change in RRMS compared to NC over 2 years. These results may reflect a treatment effect. However, due to sample size and study design, these results should be considered preliminary and await confirmation.
Literature
1.
Bakshi R, Dandamudi VS, Neema M, De C, Bermel R. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis. J Neuroimaging. 2005;15:30S–45S.CrossRefPubMed
2.
Horsfield MA, Sala S, Neema M, Absinta M, Bakshi A, Sormani MP, Rocca MA, Bakshi R, Filippi M. Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage. 2010;50:446–55.CrossRefPubMedPubMedCentral
3.
De Leener B, Kadoury S, Cohen-Adad J. Robust, accurate and fast automatic segmentation of the spinal cord. Neuroimage. 2014;98:528–36.CrossRefPubMed
4.
Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von Büdingen HC, Waubant E, Zhu AH, Goodin DS, Cree BA, Hauser SL, Henry RG. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014;76:568–80.CrossRefPubMed
5.
Gass A, Rocca MA, Agosta F, Ciccarelli O, Chard D, Valsasina P, Brooks JC, Bischof A, Eisele P, Kappos L, Barkhof F, Filippi M, MAGNIMS Study Group. MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurol. 2015;14:443–54.CrossRefPubMed
6.
Yiannakas MC, Mustafa AM, De Leener B, Kearney H, Tur C, Altmann DR, De Angelis F, Domenico P, Ciccarelli O, Miller DH, Cohen-Adad J, Gandini Wheeler-Kingshott CAM. Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to multiple sclerosis. Neuroimage Clin. 2016;10:71–7.CrossRefPubMed
7.
Chen M, Carass A, Oh J, Nair G, Phan DL, Reich DS, Prince JL. Automatic magnetic resonance spinal cord segmentation with topology constraints for variable fields of view. Neuroimage. 2013;83:1051–62.CrossRefPubMed
8.
Lin X, Tench CR, Evangelou N, Jaspan T, Constantinescu CS. Measurement of spinal cord atrophy in multiple sclerosis. J Neuroimaging. 2004;14:20S–6S.CrossRefPubMed
9.
Laule C, Vavasour IM, Zhao Y, Traboulsee AL, Oger J, Vavasour JD, Mackay AL, Li DK. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. Mult Scler. 2010;16:670–7.CrossRefPubMed
10.
Lin X, Trench CR, Turner B, Blumhardt LD, Constantinescu CS. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon β-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry. 2003;74:1090–4.CrossRefPubMedPubMedCentral
11.
Rudick RA. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging. 2004;14:54S–64S.CrossRefPubMed
12.
Filippi M, Preziosa P, Rocca MA. Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink? Curr Opin Neurol. 2014;27:290–9.CrossRefPubMed
13.
Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon β-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003;60:44–51.CrossRefPubMed
14.
Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler. 2002;5:532–3.CrossRef
15.
Bakshi R, Neema M, Tauhid S, Healy BC, Glanz BI, Kim G, Miller J, Berkowitz JL, Bove R, Houtchens MK, Severson C, Stankiewicz JM, Stazzone L, Chitnis T, Guttmann CR, Weiner HL, Ceccarelli A. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014;25:1156–61.CrossRefPubMedPubMedCentral
16.
Filippi M, Bozzali M, Horsfield MA, Rocca MA, Sormani MP, Iannucci G, Colombo B, Comi G. A conventional and magnetization transfer MRI study of the cervical cord in patients with MS. Neurology. 2000;54:207–13.CrossRefPubMed
17.
Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, Ruggieri S, Rovira A, Stippich C, Kappos L, Sprenger T, Tortorella P, Rovaris M, Gasperini C, Montalban X, Geutrs JJ, Polman CH, Barkhof F, Filippi M, Altmas DR, Ciccarelli O, Miller DH, Chard DT. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler. 2014;20:72–80.CrossRefPubMedPubMedCentral
18.
Cohen AB, Neema M, Arora A, Dell’oglio E, Benedict RH, Tauhid S, Goldberg-Zimring D, Chavarro-Nieto C, Ceccarelli A, Klein JP, Stankiewicz JM, Houtchens MK, Buckle GJ, Alsop DC, Guttmann CR, Bakshi R. The relationship among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis. J Neuroimaging. 2012;22:122–8.CrossRefPubMed
19.
Sombekke MH, Lukas C, Crusius JB, Tejedor D, Killestein J, Arteta D, Martinez A, Uitdehaag BM, Knol DL, Pena AS, Geurts JJ, De Jager PL, Barkhof F, Vrenken H, Polman CH. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol. 2009;66:1531–6.CrossRefPubMed
20.
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer III FE, Priore RL, Pullicino PM, Scherokman BJ, Weinstock-Guttman B, Whitham RH, The Multiple Sclerosis Collaborative Research Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285–94.CrossRefPubMed
21.
Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer MJ, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer III FE, Priore RL, Pullicino PM, Scherokman BJ, Weinstock-Guttman B, Whitham RH, The Multiple Sclerosis Collaborative Research Group. Magnetic resonance studies of intramuscular interferon β-la for relapsing multiple sclerosis. Ann Neurol. 1998;43:79–87.CrossRefPubMed
22.
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW, CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343:898–904.CrossRefPubMed
23.
Rudick RA, Fisher E, Lee JC, Simon J, Jabcobs L, Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology. 1999;53:1698–704.CrossRefPubMed
24.
Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L, European IFN-1a in Relapsing MS Dose Comparison Trial Study Group. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology. 2005;64:236–40.CrossRefPubMed
25.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–6.CrossRefPubMed
26.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.CrossRefPubMed
27.
Cutter GR, Baier M, Rudick R, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871–82.CrossRefPubMed
28.
Stankiewicz JM, Neema M, Alsop DC, Healy BC, Arora A, Buckle GJ, Chitnis T, Guttmann CRG, Hackney D, Bakshi R. Spinal cord lesions and clinical status in multiple sclerosis: a 1.5T and 3T MRI study. J Neurol Sci. 2009;279:99–105.CrossRefPubMedPubMedCentral
29.
Kim G, Khalid F, Oommen VV, Tauhid S, Chu R, Horsfield MA, Healy BC, Bakshi R. T1-vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis. BMC Neurol. 2015;15:124.CrossRefPubMedPubMedCentral
30.
Healy BC, Arora A, Hayden DL, Ceccarelli A, Tauhid S, Neema M, Bakshi R. Approaches to normalization of spinal cord volume: application to multiple sclerosis. J Neuroimaging. 2012;22:e12–9.CrossRefPubMed
31.
Kearney H, Miller DH, Ciccarelli O. Spinal cord MRI in multiple sclerosis –diagnostic, prognostic and clinical value. Nat Rev Neurol. 2015;11:327–38.CrossRefPubMed
32.
Brex PA, Leary SM, O’Riordan JI, Miszkiel KA, Plant GT, Thompson AJ, Miller DH. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;70:544–7.CrossRefPubMedPubMedCentral
33.
Stevenson VL, Leary SM, Losseff NA, Parker GJ, Barker GJ, Husmani Y, Miller DH, Thompson AJ. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology. 1998;51:234–8.CrossRefPubMed
34.
Rocca MA, Horsfield MA, Sala S, Copetti M, Valsasina P, Mesaros S, Martinelli V, Caputo D, Stosic-Opincal T, Drulovic J, Comi G, Filippi M. A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology. 2011;76:2096–102.CrossRefPubMed
35.
Klein JP, Arora A, Neema M, Healy BC, Tauhid S, Goldberg-Zimring D, Chavarro-Nieto C, Stankiewicz JM, Cohen AB, Buckle GJ, Houtchens MK, Ceccarelli A, Dell’Oglio E, Guttmann CR, Alsop DC, Hackney DB, Bakshi R. A 3T MR imaging investigation of the topography of whole spinal cord atrophy in multiple sclerosis. Am J Neuroradiol. 2011;32:1138–42.CrossRefPubMedPubMedCentral
36.
Kearney H, Miszkiel KA, Yiannakas MC, Ciccarelli O, Miller DH. A pilot MRI study of white and grey matter involvement by multiple sclerosis spinal cord lesions. Mult Scler Relat Disord. 2013;2:103–8.CrossRefPubMed
37.
Nair G, Absinta M, Reich DS. Optimized T1-MPRAGE sequence for better visualization of spinal cord multiple sclerosis lesions at 3T. Am J Neuroradiol. 2013;34:2215–22.CrossRefPubMedPubMedCentral
38.
Papinutto N, Schlaeger R, Panara V, Zhu AH, Caverzasi E, Stern WA, Hauser SL, Henry RG. Age, gender and normalization covariates for spinal cord gray matter and total cross-sectional areas at cervical and thoracic levels: a 2D phase sensitive inversion recovery imaging study. PLoS One. 2015;10:e0118576.CrossRefPubMedPubMedCentral
39.
Oh J, Seigo M, Saidha S, Sotirchos E, Zackowski K, Chen M, Prince J, Diener-West M, Calabresi PA, Reich DS. Spinal cord normalization in multiple sclerosis. J Neuroimaging. 2014;24:577–84.CrossRefPubMedPubMedCentral
Metadata
Title
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
Authors
Sheena L. Dupuy
Fariha Khalid
Brian C. Healy
Sonya Bakshi
Mohit Neema
Shahamat Tauhid
Rohit Bakshi
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Medical Imaging / Issue 1/2016
Electronic ISSN: 1471-2342
DOI
https://doi.org/10.1186/s12880-016-0158-4

Other articles of this Issue 1/2016

BMC Medical Imaging 1/2016 Go to the issue

Research article

The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts

Case report

Anisakiasis mimics cancer recurrence: two cases of extragastrointestinal anisakiasis suspected to be recurrence of gynecological cancer on PET-CT and molecular biological investigation

Research Article

Skeleton-based cerebrovascular quantitative analysis

Case report

Differentiation of sarcoidosis-lymphoma syndrome lesions: a case report on the use of two different positron emission tomography tracers

Case report

Counter-clockwise vortical blood flow in the main pulmonary artery in a patient with patent ductus arteriosus with pulmonary arterial hypertension: a cardiac magnetic resonance imaging case report

Research article

Development of a morphology-based modeling technique for tracking solid-body displacements: examining the reliability of a potential MRI-only approach for joint kinematics assessment